Joseph Ross, MD, MHS
Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management)Cards
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
Training
Montefiore Medical Center (2004)
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
Training
Montefiore Medical Center (2004)
Contact Info
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Education
Yale School of Medicine (2006)
Albert Einstein College of Medicine (2001)
Training
Montefiore Medical Center (2004)
About
Titles
Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management)
Biography
Joseph S. Ross, MD, MHS, is a Professor of Medicine (General Medicine) and of Public Health (Health Policy and Management), a member of the Center for Outcomes Research and Evaluation (CORE) at the Yale-New Haven Hospital, and an Co-Director of the National Clinician Scholars program (NCSP) at Yale. He completed his undergraduate degrees in biological science: neuroscience and psychology at the University of Rochester and his medical degree at the Albert Einstein College of Medicine, Bronx, NY. After completing his post-graduate training in primary care internal medicine at Montefiore Medical Center in Bronx, NY, Dr. Ross was a fellow in the Robert Wood Johnson Foundation Clinical Scholars program at Yale, earning a Master’s degree in health sciences research. Using health services research methods, Dr. Ross’s research focuses on examining factors which affect the use or delivery of recommended ambulatory care services for older adults and other vulnerable populations, evaluating the impact of state and federal policies on the delivery of appropriate and higher quality care, and addressing issues related to pharmaceutical and medical device regulation, evidence development, postmarket surveillance, and clinical adoption. In addition, he collaborates with a multi-disciplinary team of investigators under contract for the Centers for Medicare and Medicaid Services to develop statistical models that are used to measure and publicly report hospital and ambulatory care clinical outcomes using administrative data. Dr. Ross co-directs the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI), the Yale Open Data Access (YODA) Project, the Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT) at Yale Law School, and leads efforts at Yale-New Haven Health System in collaboration with the National Evaluation System for health Technology. Dr. Ross is currently a Deputy Editor at JAMA, co-founder of medRxiv, Chair of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC), and a member of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC) for ICER.
Appointments
General Internal Medicine
ProfessorPrimaryHealth Policy & Management
ProfessorSecondaryInstitution for Social and Policy Studies
ProfessorSecondary
Other Departments & Organizations
- Cancer Prevention and Control
- Center for Outcomes Research & Evaluation (CORE)
- Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT)
- General Internal Medicine
- Health Policy & Management
- Institution for Social and Policy Studies
- Internal Medicine
- National Clinician Scholars Program
- Regulatory Affairs Track
- Yale School of Public Health
- Yale Ventures
Education & Training
- MHS
- Yale School of Medicine (2006)
- Postgraduate Training
- Montefiore Medical Center (2004)
- MD
- Albert Einstein College of Medicine (2001)
- BS
- University of Rochester (1996)
- BA
- University of Rochester (1996)
Research
Overview
Medical Subject Headings (MeSH)
ORCID
0000-0002-9218-3320
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Harlan Krumholz, MD, SM
Jeph Herrin, PhD
Jennifer E Miller, PhD
Jeptha Curtis, MD
Erica Spatz, MD, MHS
Zhenqiu Lin, PhD
Quality of Health Care
Delivery of Health Care
Health Services Research
Publications
2024
Adoption of the voluntary conflict of interest statement on PubMed
Rogus S, Ross J, Lurie P. Adoption of the voluntary conflict of interest statement on PubMed. PLOS ONE 2024, 19: e0308782. PMID: 39475909, PMCID: PMC11524491, DOI: 10.1371/journal.pone.0308782.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsKidney Outcomes with GLP-1RAs, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk
Neumiller J, Herrin J, Swarna K, Polley E, Galindo R, Umpierrez G, Deng Y, Ross J, Mickelson M, McCoy R. Kidney Outcomes with GLP-1RAs, SGLT2 Inhibitors, DPP-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk. Clinical Journal Of The American Society Of Nephrology 2024 DOI: 10.2215/cjn.0000000587.Peer-Reviewed Original ResearchAltmetricConceptsSodium-glucose co-transporter 2 inhibitorsGlucagon-like peptide-1 receptor agonistsSodium-glucose co-transporter 2Dipeptidyl peptidase-4 inhibitorsGlucagon-like peptide-1Dipeptidyl peptidase-4Receptor agonistsPrimary composite outcomeKidney replacement therapyChronic kidney diseaseComposite outcomeSecondary composite outcomeType 2 diabetesGLP-1 receptor agonist therapyCVD riskCardiovascular diseaseModerate CVD riskPrescribed glucose-lowering agentsBaseline CVD riskHigh-risk patientsAssociated with risk reductionCKD stage 3Retrospective observational studyGlucose-lowering agentsModerate cardiovascular riskModernizing Medical Device Regulation: Challenges and Opportunities for the 510(k) Clearance Process.
Kadakia K, Rathi V, Dhruva S, Ross J, Krumholz H. Modernizing Medical Device Regulation: Challenges and Opportunities for the 510(k) Clearance Process. Annals Of Internal Medicine 2024 PMID: 39374526, DOI: 10.7326/annals-24-00728.Peer-Reviewed Original ResearchAltmetricAt-Home Testing for Survivors of Sexual Assault—Empowerment or Exploitation?
Kadakia K, Ross J, Ramachandran R. At-Home Testing for Survivors of Sexual Assault—Empowerment or Exploitation? JAMA Internal Medicine 2024, 184: 1153-1155. PMID: 39133501, DOI: 10.1001/jamainternmed.2024.2883.Peer-Reviewed Original ResearchAltmetricConceptsUse of electronic health records to characterize patients with uncontrolled hypertension in two large health system networks
Lu Y, Keeley E, Barrette E, Cooper-DeHoff R, Dhruva S, Gaffney J, Gamble G, Handke B, Huang C, Krumholz H, McDonough C, Schulz W, Shaw K, Smith M, Woodard J, Young P, Ervin K, Ross J. Use of electronic health records to characterize patients with uncontrolled hypertension in two large health system networks. BMC Cardiovascular Disorders 2024, 24: 497. PMID: 39289597, PMCID: PMC11409735, DOI: 10.1186/s12872-024-04161-x.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsElectronic health recordsHealth recordsHealth systemUncontrolled hypertensionUse of electronic health recordsHypertension managementElectronic health record systemsOneFlorida Clinical Research ConsortiumElectronic health record dataYale New Haven Health SystemBP measurementsICD-10-CM codesHealth system networkPublic health priorityICD-10-CMIncidence rate of deathElevated BP measurementsElevated blood pressure measurementsHealthcare visitsAmbulatory careHealth priorityRetrospective cohort studyEHR dataOneFloridaBlood pressure measurementsClass I Recalls of Cardiovascular Devices Between 2013 and 2022 : A Cross-Sectional Analysis.
See C, Mooghali M, Dhruva S, Ross J, Krumholz H, Kadakia K. Class I Recalls of Cardiovascular Devices Between 2013 and 2022 : A Cross-Sectional Analysis. Annals Of Internal Medicine 2024 PMID: 39284187, DOI: 10.7326/annals-24-00724.Peer-Reviewed Original ResearchAltmetricConceptsCross-sectional studyCross-sectional analysisAdverse health consequencesPatient safetyClinical testingClass IHealth consequencesClinical evidenceFDA summariesPostapproval studiesDecision summariesFood and Drug AdministrationU.S. Food and Drug AdministrationEnd-point selectionPremarket approvalMultiple class IClinical studiesPostmarketing surveillanceSummaryDrug AdministrationMedical device recall databaseRecallPatientsFDAPostmarketingRetraction of publications in Spain: A retrospective analysis using the Retraction Watch database
Candal-Pedreira C, Ross J, Rey-Brandariz J, Ruano-Ravina A. Retraction of publications in Spain: A retrospective analysis using the Retraction Watch database. Medicina Clínica 2024 PMID: 39277442, DOI: 10.1016/j.medcli.2024.07.003.Peer-Reviewed Original ResearchAltmetricComparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM
Khera R, Aminorroaya A, Dhingra L, Thangaraj P, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand T, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Kaur G, Lau W, Li J, Li K, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLeggon J, McLemore M, Minty E, Morales D, Nagy P, Ostropolets A, Pistillo A, Phan T, Pratt N, Reyes C, Richter L, Ross J, Ruan E, Seager S, Simon K, Viernes B, Yang J, Yin C, You S, Zhou J, Ryan P, Schuemie M, Krumholz H, Hripcsak G, Suchard M. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM. Journal Of The American College Of Cardiology 2024, 84: 904-917. PMID: 39197980, DOI: 10.1016/j.jacc.2024.05.069.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsGLP-1 RAsSecond-line agentsGLP-1Antihyperglycemic agentsCardiovascular diseaseMACE riskGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsEffects of SGLT2isType 2 diabetes mellitusPeptidase-4 inhibitorsAdverse cardiovascular eventsCox proportional hazards modelsRandom-effects meta-analysisCardiovascular risk reductionTarget trial emulationProportional hazards modelFloods and cause-specific mortality in the United States during 2001-2020
Chu L, Warren J, Spatz E, Lowe S, Lu Y, Ma X, Ross J, Krumholz H, Chen K. Floods and cause-specific mortality in the United States during 2001-2020. ISEE Conference Abstracts 2024, 2024 DOI: 10.1289/isee.2024.1705.Peer-Reviewed Original ResearchPremarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies
Mooghali M, Wallach J, Ross J, Ramachandran R. Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies. JAMA Network Open 2024, 7: e2430486. PMID: 39190303, PMCID: PMC11350476, DOI: 10.1001/jamanetworkopen.2024.30486.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsFood and Drug Administration tableFood and Drug AdministrationSurrogate end pointsSurrogate markerPostmarketing studiesEnd pointsTraditional approvalCross-sectional studyClinical benefitAccelerated approvalTherapy designClinically significant end pointsReview of therapeuticsPrimary end pointUS Food and Drug AdministrationTrial end pointsSignificant end pointsPostmarketing requirementsPreliminary clinical evidenceApproval pathwayPivotal trialsClinical evidenceBreakthrough therapiesDrug AdministrationTherapy
Academic Achievements & Community Involvement
activity JAMA
Journal ServiceDeputy EditorDetails06/01/2023 - Presentactivity BMJ
Journal ServiceAssociate EditorDetails2020 - 2023activity JAMA Internal Medicine
Journal ServiceAssociate EditorDetails04/01/2013 - 12/31/2019activity Journal of General Internal Medicine
Journal ServiceDeputy EditorDetails2011 - 2013
News
News
- October 28, 2024Source: Yale Daily News
Yale experts weigh in on Harris’ Medicare expansion plan
- October 14, 2024Source: BioSpace
5 Accelerated Approvals Gone Wrong
- September 09, 2024Source: STAT
Apple Pushes into Sleep Apnea Detection but Health Care Integration Remains Unclear
- August 17, 2024Source: New York Times
The painkiller used for just about anything
Get In Touch
Contacts
General Internal Medicine
P.O. Box 208093
New Haven, CT 06520-8093
United States
Locations
E.S. Harkness Memorial Hall, Building A
Academic Office
367 Cedar Street, Ste 405B
New Haven, CT 06510